Acquired Immunodeficiency Syndrome ; diagnosis ; drug therapy ; Adolescent ; Antiretroviral Therapy, Highly Active ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Male

OBJECTIVE:To establish a determination method for trace elements of Plumbago zeylanica. METHODS:Induct- ively coupled plasma emission spectrum (ICP-AES) was used to determine seven trace elements of P. zeylanica, i.e. Cu, Zn,Fe,Ca,Mg,Mn and Sr simultaneously. Se was determined by atomic fluorescence (AFS) method. RESULTS: The RSD ranged from 0.78% to 3.01%(n=5),while the recovery was within 91.9%～105.8%. The result obtained was satisfactory. Se took a large proportion in P. zeylanica, followed by Cu,Zn,Fe,Ca,Mg,Mn,Sr.CONCLUSION: The method is brief, rapid and accurate for the determination of P. zeylanica. The study provide reference for future pharmacological study of P. zeylanica.

Excimer laser was found in 1975, and has been used in corneal refractive surgery, which made a great progress and become rapidly developed. ArF laser of 193 nm has high accuracy because it can gasify corneal tissue molecule. Moreover, it does not produce heat effect on tissues surrounding irradiated sites, so not produce adverse effect on corneal structure. At present, excimer laser has been successfully used in corneal radial incision, excimer laser corneal refractive surgery, laser in situ keratomileusis, laser epithelial keratomileusis and laser subepithelial keratomileusis. With increasing understanding of excimer laser and accumulating clinical experience, novel, accurate and predictive excimer laser corneal refractive surgery will be developed.

Delivery of Health Care ; legislation & jurisprudence ; methods ; Female ; Forecasting ; Health Services for the Aged ; legislation & jurisprudence ; supply & distribution ; Humans ; Male ; Medical Informatics ; Prostatic Intraepithelial Neoplasia ; pathology ; Prostatic Neoplasms ; pathology ; Time Factors

China ; Humans ; Immunohistochemistry ; standards ; Pathology, Clinical ; methods ; Quality Control

Objective To evaluate the effectiveness and safety of a new designed balloon catheter, the Minirail balloon catheter in coronary intervention Methods Twenty two consecutive patients with coronary artery disease (male 16, female 6, mean age 58 77?8 69 years) were enrolled the study Selective angioplasty was performed for 24 target lesions (17 in LAD, 2 in LCX, and 5 in RCA) Among these target lesions were 5 type C, 14 type B 2, and 5 type B 1 lesions The average extent of narrowing before procedure was 91 18%?5 95% Target lesions were dilated with Minirail balloon catheters Results All of the target lesions were successfully dilated with Minirail balloon catheters The average residual stenosis was 33 18%?25 14% after balloon angioplasty Significant dissection was seen in 3 of the cases, and slow reflow in another one Twenty four stents were implanted in 19 cases The final residual stenosis was 1 82%?5 01% at the end of procedure No death or Q wave myocardial infarction happened No emergency bypass surgery needed Conclusion Minirail balloon catheter is safe, effective, and easy to be used in coronary intervention

Objective To summarize the effect and safety of percutaneous coronary intervention (PCI) for CHD in patients with single patent coronary artery. Methods We collected the data of CHD in 10 patients with single patent coronary artery who underwent PCI and analyzed them retrospectively. Results All patients with single patent coronary artery had successful PCI. Symptoms of all the CHD patients had been significantly relieved after PCI. No major adverse cadiac events occurred in hospitalization. Conclusion The data suggest that the patients with single patent coronary artery might be treated with PCI effectively and safely.

Objective To investigate the effectiveness, dose-effect and time-effect relationships for inhibiting neointimal proliferation by 103 Pd radioactive stent, and the safety of the radioactive stent. Methods By angiogaphic, morphometric and histopathologic analysis, we compared 1?000 ?Ci, 500 ?Ci and 100 ?Ci 103 Pd stents with non-radioactive stents on 5 weeks and 12 weeks after stenting in a micro-porcine coronary model of restenosis. Results The neointimal areas of 500 ?Ci and 100 ?Ci 103 Pd stents were significantly smaller than control stents. 1?000 ?Ci stents and control stents had similar neointimal areas. The neointimal areas of 500 ?Ci stents were significantly smaller than 100 ?Ci stents. Compared with control stents, 500 ?Ci stents reduced the neointimal areas by 49% and 50% respectively on 5 weeks and 12 weeks after stenting. Compared with 5 weeks after stenting, the effect of inhibiting neointimal proliferation by 100 ?Ci stents was reduced by 56% (32% vs 14%) on 12 weeks. The neointimal areas on both edge of 100 ?Ci stents were significantly larger than control stents. The neointimal areas on both edge of 1?000 ?Ci stents and 500 ?Ci stents were similar with control stents. No evident radiation damage had been found in the experimental animals who had 103 Pd stent. Conclusion There may be an effective dose window for 103 Pd radioactive stent in inhibiting neointimal proliferation. The effect of inhibiting neointimal proliferation was dose dependent. 103 Pd radioactive stent with appropriate activities may effectively, persistently inhibit neointimal proliferation with no adverse radiation sequelae. These results suggest that 103 Pd radioactive stent prevent restenosis. These data may be useful in predicting safe and effective activity for 103 Pd radioactive stent.

Objective To determine the efficacy of stent based rapamycin (Rapa) and methotrexate (MTX) alone or in combination of them to reduce in stent neointimal hyperplasia Rapamycin is a potent immunosuppressive agent that inhibits smooth muscle cell (SMC) proliferation by blocking cell cycle progression Methods Stents were coated with PLGA (poly/lactic co glycolic acid) polymer containing 68-96 ?g Rapa or 250-300 ?g MTX or 58-81 ?g Rapa and 120-170 ?g MTX respectively Twenty five stents (metal, n =8; MTX, n =5; Rapa, n =7; Rapa and MTX, n =5) were implanted in the coronary arteries of 25 pigs Results After 28 days, the mean neointimal thickness was (2 18?1 03) mm 2 in the bare metal stent group; (0 94?0 88) mm 2 in the Rapa group; (0 47?0 24) mm 2 in the combination Rapa and MTX group, (3 93?1 48) mm 2 in the MTX group Compared with metal group the mean neointimal thickness was significantly decresed in Rapa groups and combined group The in stent restenosis was 25% (2/8) in metal group and 80% (4/5) in MTX group after 28 days, and there was no restenosis in the other two groups Conclusion Stent based delivery of Rapa via PLGA polymer can feasibly and effectively reduce in stent neointimal hyperplasia by inhibiting cellular proliferation However there are no effects to reduce in stent neointimal hyperplasia by MTX eluting stents in this study

Objective To investigate the anti-proliferation effect of triptolide-eluting stent, as well as its effectiveress, dose-effect relationship and safety. Methods Experimental stents were divided into 4 groups with 10 stents each, namely bare stent group, sirolimus-coated stent group, 5.6 ?g triptolide-coated stent group and 56 ?g triptolide-coated stent group. By morphometric and histopathologic analysis,we compared 5.6 ?g and 56 ?g triptolide-eluting stents with bare metal stents and sirolimus-eluting stents 28 days after stenting in rabbit iliac models of restenosis. Results The neointimal area of 5.6 ?g triptolide-eluting stents was similar to that of bare metal stents, but larger than that of sirolimus-eluting stents. The neointimal area of 56 ?g triptolide-eluting stents was smaller than that of bare metal stents and 5.6 ?g triptolide-eluting stents, but was similar to that of sirolimus-eluting stents. In all the groups, proliferation on both edges of the stents was insignificant. No toxic effect had been found in the experimental animals related to triptolide-eluting stent. Conclusion Triptolide-eluting stents may inhibit neointimal proliferation. The effect of inhibiting neointimal proliferation is dose dependent and with no adverse effect. These results suggest that triptolide-eluting stent can prevent restenosis within four weeks.